Bone regeneration and repair are among the most challenging clinical challenges to overcome. Despite extensive research on bone-tissue repair and regeneration, it remains difficult to achieve perfect regeneration and repair of bone tissue using the current treatments. One new treatment is bone-tissue engineering (TE), which has attracted attention because of its low invasiveness. Silk fibroin (SF), a high-molecular-weight natural fibrous protein secreted by silkworms and spiders, is an ideal choice for melt electrowriting (MEW) of bone TE scaffolds owing to its superior mechanical properties, controlled biodegradation rate, and high biocompatibility. It contains 18 essential amino acids and is widely used in bone grafting. Their physical and chemical properties may be essential for stem cell growth and differentiation, making them ideal scaffold materials for bone TE. In this review, the three primary components of bone TE and the bone-healing process are presented. With an emphasis on recent advancements and the use of bone TE, both in vitro and in vivo, we examined the use of SF in bone TE from the standpoint of its origin and structure. To offer new concepts and avenues for related research, we have also looked at the possible topics for SF research and the present difficulties.
23 November 2022 in Journal of Materials Chemistry B
Combined chemo/gene therapy of cancer through different action mechanisms has been emerging to enhance the therapeutic efficacy towards cancer, and still remains a challenging task due to the lack of highly effective and biocompatible nanocarriers. In this work, we report a new nanosystem based on amphiphilic phosphorus dendron (1-C12G1) micelles to co-deliver microRNA-21 inhibitor (miR-21i) and doxorubicin (DOX) for combination therapy of triple negative breast cancer. The amphiphilic phosphorus dendron bearing a long linear alkyl chain and ten protonated pyrrolidine surface groups was prepared and was demonstrated to form micelles in water solution and have a hydrodynamic size of 103.2 nm. The micelles are shown to be stable, enable encapsulation of an anticancer drug DOX with optimal loading content (80%) and encapsulation efficiency (98%), and can compress miR-21i to form polyplexes to render it with good stability against degradation. The co-delivery system of 1-C12G1@DOX/miR-21i polyplexes has a pH-dependent DOX release profile, and can be readily phagocytosed by cancer cells to inhibit them due to the different anticancer mechanisms, which was further validated after intravenous injection to treat an orthotopic triple-negative breast tumor model in vivo. With the proven biocompatibility under the studied doses, the developed amphiphilic phosphorus dendron micelles could be developed as an effective nanomedicine formulation for synergistic cancer therapy.
The development of efficient nanomedicines to repress the repolarization of M1 phenotype macrophages and therefore inhibit pro-inflammatory cytokine overexpression for anti-inflammatory therapy is still a challenging task. We report here an original gene delivery nanoplatform based on pyrrolidinium-modified amphiphilic generation 1 phosphorus dendron (C12G1) nanomicelles with a rigid phosphorous dendron structure. The nanomicelles display higher gene delivery efficiency than the counterpart materials of pyrrolidinium-modified G1 phosphorus dendrimers, and meanwhile exhibit excellent cytocompatibility. The C12G1 nanomicelles can be employed to co-deliver the miRNA-146a mimic (miR-146a mimic) and miRNA-429 inhibitor (miR-429i) to inhibit the Toll-like receptor-4 signaling pathway and p38 mitogen-activated protein kinase signaling pathway, respectively, thus causing repression of M1 phenotype alveolar macrophage polarization. The developed C12G1/miR-mixture polyplexes enable efficient therapy of lipopolysaccharide-activated alveolar macrophages in vitro and an acute lung injury mouse model in vivo. The generated cationic phosphorus dendron nanomicelles may hold promising potential for anti-inflammatory gene therapy of other inflammatory diseases.
Nanoplatforms with amplified passive tumor targeting and enhanced protein resistance can evade unnecessary uptake by the reticuloendothelial system and achieve high tumor retention for accurate tumor theranostics. To achieve this goal, we here constructed phosphorus core–shell tecto dendrimers (CSTDs) with a rigid aromatic backbone core as a nanoplatform for enhanced fluorescence and single-photon emission computed tomography (SPECT) dual-mode imaging of tumors. In this study, the phosphorus P-G2.5/G3 CSTDs (G denotes generation) were partially conjugated with tetraazacyclododecane tetraacetic acid (DOTA), cyanine5.5 (Cy5.5) and 1,3-propane sulfonate (1,3-PS) and then labeled with 99mTc. The formed P-G2.5/G3-DOTA-Cy5.5-PS CSTDs possess good monodispersity with a particle size of 10.1 nm and desired protein resistance and cytocompatibility. Strikingly, compared to the counterpart material G3/G3-DOTA-Cy5.5-PS with both the core and shell components being soft poly(amidoamine) dendrimers, the developed P-G2.5/G3-DOTA-Cy5.5-PS complexes allow for more efficient cellular uptake and more significant penetration in 3-dimensional tumor spheroids in vitro, as well as more significant tumor retention and accumulation for enhanced dual-mode fluorescence and SPECT (after labelling with 99mTc) tumor imaging in vivo. Our studies suggest that the rigidity of the core for the constructed CSTDs matters in the amplification of the tumor enhanced permeability retention (EPR) effect for improved cancer nanomedicine development.
Overcoming the albumin–bilirubin binding barrier to achieve specific recognition and high-efficiency capture of blood bilirubin remains a major clinical challenge in treating patients with hyperbilirubinemia due to liver failure, cholestasis, or other related conditions. Here, a molecular engineering-assisted functionalization strategy is proposed: programming the coordination environment of nanocrystalline frameworks with monodentate carboxylic acid ligands of varied carbon chain lengths to construct a family of zirconium-based UiO-66 nanoporous frameworks that act as bilirubin-specific molecular capture traps. The experimental results and molecular dynamics simulations confirm that the newly engineered UiO-66 nanoporous framework rapidly enriched albumin-bound bilirubin through short-range van der Waals/electrostatic effects; the internal Zr–μ 3 –OH sites then formed directional Zr–pyrrole coordination with the bilirubin tetrapyrrole core, whereas albumin was physically excluded by the narrow apertures of the engineered nanoporous framework (average 7.6 Å), breaking the “albumin barrier” without competitive displacement. Dense intrapore hydrogen-bonding networks and π–π stacking further strengthen bilirubin-specific complexation. The computed adsorption energy (ΔE ads = – 3.7 eV) indicates spontaneous, diffusion-limited capture. In simulated blood experiments, the newly developed UiO-66 nanoporous framework achieves an ultrahigh bilirubin removal rate of ~ 97.9% with negligible albumin loss. Finally, clinical tests on plasma samples from ten liver failure patients revealed a 251% higher bilirubin removal capacity per unit mass than that of the commercial ion exchange resin (IER) within 3 h, while albumin leakage remained ≤ 2.58% (vs. ≥ 8.53% for commercial IER). This study reveals, for the first time, the advantages and translational prospects of molecularly engineered nanocrystalline frameworks as a clinically viable platform for high-efficiency blood bilirubin removal."Image missing"